Home » Newsletters » BioWorld Science

BioWorld Science

May 17, 2012

View Archived Issues

Novartis identifies new class of compounds for treating cystic fibrosis

Daiichi Sankyo profiles highlights of fiscal 2011

Roche reports novel agents for raising HDL cholesterol

First results for phase II COMPLETE study of eculizumab presented

Genetic basis of TAR syndrome uncovered

Dainippon Sumitomo Pharma updates activities of fiscal 2011

Spanish researchers patent new agents for Gaucher's disease

Novel monoglyceride lipase inhibitors presented by Janssen Pharmaceutica

Elevation Pharmaceuticals reports phase IIb results for EP-101 in COPD

InterMune patents new agents for hepatitis and liver disorders

Cytomedix expands phase II RECOVER-Stroke study

Astellas Pharma and CoMentis present novel compounds for Alzheimer's disease

Biosceptre collaborates with Australian facilities on cancer antibody research

Achaogen provides update on plazomicin and ACHN-975 programs

New inhibitors of serotonin receptor binding synthesized at Epiomed Therapeutics

Abbott presents clinical results for their antiviral candidate ABT-072

Major Alzheimer's disease prevention study commences

Fibrocell Science enters two new agreements

Pfizer reports topline results from phase III Torisel study

Antibodies targeting misfolded Fas receptor protein disclosed

BG Medicine obtains expanded indication for Galectin-3 test in E.U., files for clearance in U.S.

Repros submits documents to FDA for Androxal SPA

Amgen provides updated blinatumomab results

Neuren Pharmaceuticals and FDA hold pre-IND meeting for NNZ-2566

Ark Therapeutics gives update on VEGF-D adenoviral vector treatment study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 29, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...